[1]DoiT , YamadaG , MizunoM , etal.Immunohistochemicalstudyofthedistributionofintercellularadhesionmolecule-1andlymphocytefunction-associatedantigen-1inchronictypeBhepatitis[J].JGastroenten terol, 1994, 29∶164-171.
|
[2]MaliziaG , Dino0, PisaR , etal.ExpressionofleukocyteadhesionmoleculesintheliverofpatientswithchronichepatitisBvirusinfection[J].Gastroenterol, 1991, 100∶749.
|
[3]HirokoTsutsui, KiyoshiMatsui, HarukiOkamura, etal.Pathophysiolog icalrolesofinterleukin-18ininflammatoryliverdiseases[J].Immuno logicalReviews2000Vol.174∶192-209.
|
[4]病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329.
|
[5]DaoT , OhashiK , KayanoT , etal.Interferon-rinducingfactor, anov elcylokine, enhancesFasligandmediatedcytotoxiicityofmurineThelperlcell[J].CellImmunol, 1996, 173∶230.
|
[6]TsutsuiH , KayagakiN , KuidaK , etal.Caspase-1-indendent, Fasfasligand-mediatedIL -18secretionfrommacrophagescausesacuteliverinjuryinmice[J].Immunity, 1999, 11 (3) ∶359-67.
|
[7]潘红英.IL -18与肝损伤机理研究进展[J].浙江医学, 2000, 22 (11) ∶702-703
|
[1] | Long LIU, Ke SHI, Qun ZHANG, Chongping RAN, Jie HOU, Yi ZHANG, Xianbo WANG. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(7): 1589-1593. doi: 10.3969/j.issn.1001-5256.2021.07.022 |
[2] | Wang Fang, Quan ZuoHua, Yang XingKun, Kou JunFeng, Yun ShengHao, Cai GuoFang, Zhou XinRen. Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1118-1120. doi: 10.3969/j.issn.1001-5256.2016.06.019 |
[3] | Yan ShuangHuan, Zhang XinYuan, Cao ZhiChen, Chen CuiYing, Wang SuPing, Tang YaFang. Relationship between the Antiviral Effect and Changes of Th1/Th2 during the Treatment of Chronic Hepatitis B Using Lamivudine.[J]. Journal of Clinical Hepatology, 2009, 25(3): 170-172. |
[4] | Liu Wei, Liu ShangZhong, Jiang ShuiYing, Sun DaYu. Changes and significance of plasm endotoxin and PDGF in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(1): 37-38. |
[9] | Ni HongYing, Huang WenQi, Chen ZhangRong, Pei Bin. The change and significance of soluble HLA class I antigen level in treatment of chronic hepatitis B with IFN-α[J]. Journal of Clinical Hepatology, 2005, 21(2): 85-86. |
[10] | Xu QingTian, Wu YanXia, Liu ChunLi, Cui ZhongFeng, Li XinYue, Xiong FeiSheng. Relationship between clinics and the content of serum HBV DNA in different clinical types of chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2004, 20(6): 343-344. |
[11] | Zhang Wei, Zhang ShiLan, Wang HaiBin. Detection and significance of plasma procalcitonin and soluble intercellular adhesion molecule-1 in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 23-24. |
[13] | Wei LiJing, Xu Wei, Wei LiQin, Niu ChunHui. Soluble intercellular adhesion molecule-1, Hyaluronic acid and their clinical signifieance in liver cirrhosis[J]. Journal of Clinical Hepatology, 2003, 19(4): 234-235. |
[17] | Du WeiBo, Xu Jie, Gan JianHe, Wu JianCheng, Yu XianHuai. The change of serum IL-12 and IL-18 level in patients with viral hepatitis and hepatic cirrhosis[J]. Journal of Clinical Hepatology, 2002, 18(4): 215-216. |
[18] | Wen WeiQun, Zhang Lian, Hu ZhangYong, Zhang MingXia, Xiao Hong, Luo KangXian. Clinical Studies on the relationship of Interleukin 18 expression and HBV infection[J]. Journal of Clinical Hepatology, 2001, 17(4): 224-226. |
[19] | Yin HongZhu, Liu JinXing, Cao ZhiChen, Li BingShun, Tang HuiHua, Feng ZhongJun. The Study of the role of Soluble Intercellular Adhesion Molecule-1 in Patients with Chronic hepatitis B[J]. Journal of Clinical Hepatology, 2000, 16(4): 230-231. |